Adage Capital Partners’s bluebird bio BLUE Stock Holding History

Adage Capital Partners’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-31,300	Closed	-$4.33M	–	927
2022 Q4	$4.33M	Buy	+31,300	New	+$4.41M	0.01%	765
2020 Q3	–	Sell	-28,940	Closed	-$22.9M	–	762
2020 Q2	$22.9M	Sell	28,940 -71,852	-71%	-$54.2M	0.06%	356
2020 Q1	$60M	Buy	100,792 +78,790	+358%	+$76.8M	0.18%	145
2019 Q4	$25M	Buy	+22,002	New	+$23.9M	0.06%	339
2018 Q3	–	Sell	-7,512	Closed	-$15.3M	–	716
2018 Q2	$15.3M	Buy	+7,512	New	+$17.1M	0.04%	471
2015 Q4	–	Sell	-3,574	Closed	-$3.96M	–	690
2015 Q3	$3.96M	Buy	3,574 +46	+1%	+$83.9K	0.01%	631
2015 Q2	$7.7M	Buy	+3,528	New	+$7.19M	0.02%	586

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Adage Capital Partners's BLUE Position: Q1 2023 in Review

Adage Capital Partners sold out of bluebird bio (BLUE) in Q1 2023, closing a stake of 31,300 shares — an estimated $4.33M sold.

Adage Capital Partners first reported a position in BLUE in Q2 2015 and held it in 7 quarters. The position peaked at $60M in Q1 2020. 177 funds tracked by Wall St. Rank hold BLUE as of Q1 2023.

Adage Capital Partners reported no remaining bluebird bio position as of Q1 2023 after selling out during the quarter.
Adage Capital Partners sold 31,300 bluebird bio shares in Q1 2023, an estimated $4.33M.
Adage Capital Partners first reported a position in bluebird bio in Q2 2015 and held it in 7 quarters.
Adage Capital Partners's bluebird bio position peaked at $60M in Q1 2020.
177 funds tracked by Wall St. Rank held bluebird bio as of Q1 2023.

Based on Adage Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.